Cases
Representative Matters: Represented Integral Molecular, a biotechnology company specializing in discovering therapeutic antibodies-
the industry leader in membrane protein solutions-in its research collaboration
licensing agreement with Context Therapeutics, a clinical-stage women's oncology company, to advance a potential gynecological cancer therapy involving an anti-claudin 6 (CLDN6) bispecific monoclonal antibody.
Represented AgriMetis, LLC, a company working to fulfill the emerging need for sustainable crop protection products by applying cutting-edge technology
novel business models, in connection with the sale of its lead asset
related product development program to BASF, the German multinational chemical company.
Represented Annovis Bio, Inc. (NYSEAMERICAN: ANVS ), a manufacturer of pharmaceuticals for the treatment of neurodegenerative diseases, in connection with its initial public offering.
Represented Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, in its $25 million Series C Preferred Stock extension financing, with Vensana Capital as the lead investor. Vensana was joined by existing investors, including New Enterprise Associates, H.I.G. Bioventures,
Quaker Partners.
Represented Complexa Inc., a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis
inflammation-associated orphan diseases, in connection with a $28 million Series C-1 Preferred Stock financing, of which approximately $12 million was sold at the initial closing. The financing was led by New Enterprise Associates
Pfizer Venture Investments, LLC. Participation in the financing also included BioDiscovery 5 represented by Andera Partners, HBM Healthcare Investments Ltd.
JAFCO Investment Ltd. The financing was a follow-on investment to the Company's sale of $40.261 million of Series C Preferred Stock in July 2016 to the same lead investors.
Represented Vesper Medical, Inc., a private medical device company developing innovative venous stent solutions for peripheral vascular disease, in its $37 million Series B Preferred Stock financing. Lead investors Vensana Capital
Gilde Healthcare were joined by existing investors New Enterprise Associates
Quaker Partners.
Represented Tangen Biosciences, Inc., a molecular diagnostic company, in its $9 million Series A Preferred Stock financing. The financing was led by Connecticut Innovations, with participation by existing
new investors, including VC23, Axiom,
Leading Edge Ventures.
Represented VenatoRx Pharmaceuticals, Inc., a biopharmaceutical company developing next-generation antibiotics, in connection with the sale of $42 million of Series B Preferred Stock to various investors, including Abingworth, Foresite Capital
lead investor Versant Ventures, with an additional $5 million follow-on investment of Series B Preferred Stock by Everest Medicines II Limited.
Represented a pharmaceutical company developing injectable products to treat allergic reactions in its acquisition by a developer of specialty pharmaceutical products
the transaction included significant upfront cash consideration, additional milestone payments,
contingent consideration based on product sales.
Represented Psyadon Pharmaceuticals, Inc. in its acquisition by a subsidiary of Paragon Biosciences, bringing with it rights to develop, register
market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome.
Represented AgriMetis, LLC, a private company innovating agricultural crop protection products, in its $23.5 million Series B financing, in which new investors
company's co-founders participated
h
led ongoing negotiations with collaborative
strategic alliances.
Represented Strata Skin Sciences, Inc. (SSKN: Nasdaq), a dermatology
plastic surgery company, in a $17 million common stock financing led by Accelmed Growth Partners, an investment firm focused on medical technologies, which resulted in the appointment of a new CEO
a restructuring of the Board of Directors.
Represented CD Diagnostics, Inc., a Delaware-based diagnostics company focused on developing immunoassays
biomarker testing to inform treatment decisions that improve patient outcomes, in its sale to Zimmer Biomet Holdings, Inc. (NYSE
SIX: ZBH), a global leader in musculoskeletal healthcare.
Represented Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) in a follow-on underwritten public offering of four million shares of common stock at a price of $9.50 per share, with expected gross proceeds of $38 million.
Represented Inovio Pharmaceuticals, Inc. in entering into an agreement to gain all of Bioject Medical Technologies' assets for $4.5 million in stock
$1 million in cash. Inovio plans to launch a device combining its needleless, skin-surface electroporation technology with Bioject's jet injection technology.
Represented MELA Sciences, Inc. (NASDAQ:MELA) in its purchase of the XTRAC
VTRAC Dermatology business from PhotoMedex, Inc. for $42.5 million in cash
the assumption of certain business-related liabilities
the related financing with institutional investors consisting of a private placement of $42.5 million aggregate principal amount of senior secured notes
convertible debentures
warrants to purchase 3.0 million shares of common stock.
Represented Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, in its $38.9 million Series B Preferred Stock financing to accelerate the development
FDA approval of the company's endovascular dissection repair technology.
Represented Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) in its public offering of 10.925 million shares of its common stock for total gross proceeds of $87.4 million.
Represented Current Analysis, Inc., an IT
telecom market-research firm, in the sale of the company to Progressive Digital Media Group through a merger transaction for a purchase price of $19.6 million.
Represented Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) in an underwritten public offering, the gross proceeds of which were approximately $64 million.
Represented Gliknik Inc., a privately held biopharmaceutical company, in negotiating an exclusive worldwide license agreement with Pfizer Inc. for Gliknik's recombinant stradomer GL-2045, a drug c
idate designed to replace
improve on pooled human intravenous immunoglobulin (IVIG). Gliknik received an upfront payment of $25 million
is eligible to receive development, regulatory
commercial milestone payments
tiered, double-digit royalties on net sales of any products commercialized under the license agreement.
Represented Inovio Pharmaceuticals, Inc. with regard to a collaboration agreement with Roche to research, develop
commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer (INO-5150)
hepatitis B (INO-1800) as well as use of Inovio's CELLECTRA electroporation technology for delivery of the vaccines. The deal called for Inovio to receive an up-front payment of $10 million, as well as milestone payments of up to $412.5 million.
Counsel to Celator Pharmaceuticals, Inc. (NASDAQ - CPXX), which is developing oncology drugs, in transitioning from a venture-financed company to a public company
raising more than $125 million in several rounds of financing from venture capital
other accredited investors since 2005. Celator evolved from technology developed at the British Columbia Cancer Agency
maintains a subsidiary in Vancouver, British Columbia. The Series B round included a completed cross-border restructuring. After subsequent venture financings, we represented Celator in attaining status as a public company through a Form 10 filing, followed by a $39.3 million private placement led by Valence Life Sciences.
Represented Marinus Pharmaceuticals, Inc., a neuroactive steroid developer, in its $21 million Series C financing from U.S. venture capital firm Domain Associates, LLC, Russian state-owned investment fund RusnanoMedInvest,
co-investors Canaan Partners, Sofinnova Ventures
Foundation Medical Partners.
Counsel to Novira Therapeutics, Inc., an antiviral drug discovery company developing first-in-class antiviral therapeutics for the treatment of chronic HBV
HIV infections, in a $25 million Series A Preferred Stock financing, which was invested in two tranches in August 2012
February 2013, respectively.
Represented CD Diagnostics, Inc., a diagnostics company, in its Series A preferred stock financing
a strategic partnership with Zimmer Inc.
Represented Bioconnect Systems, Inc., a medical device firm, in raising $9.1 million in a private stock sale.
Represented Agile Therapeutics, Inc., a transdermal contraceptive patch developer, in more than $100 million preferred stock financing
numerous strategic relationships
other business transactions.
Counsel to Inovio Pharmaceuticals Inc., a publicly traded biotechnology company focused on the development of DNA vaccines. Inovio was formed in 2008 upon the merger of equals of Inovio Biomedical Corporation
VGX Pharmaceuticals, Inc. Served as counsel to VGX Pharmaceuticals in the merger
as outside corporate counsel to VGX Pharmaceuticals for several years prior thereto.
Represented Protez Pharmaceuticals, Inc. in two rounds of Preferred Stock financing from venture capital investors
its acquisition by Novartis Pharmaceuticals Corporation, a structured acquisition with a $100 million up-front payment. Counsel to Protez Pharmaceuticals in venture capital financings
business initiatives for several years prior to its sale.
Represented Prinston Pharmaceutical, a generic drug company subsidiary of China-based Zhejiang Huahai Pharmaceutical Ltd., in the acquisition from Par Pharmaceutical of a drug manufacturing plant in Charlotte, N.C.
the right to produce
market 18 generic medicines.
Represented Psyadon Pharmaceuticals in an in-license of a drug compound from Schering Corporation (now Merck).
Counsel to a start-up pharmaceutical company in its licensing agreement from the University of Chicago. Also represent the client in an ongoing search for its seed round of venture capital financing to enable it to commercialize preventative treatments for necrotizing enterocolitis
inflammatory bowel disease.
Counsel to emerging businesses in structuring, negotiating
drafting venture capital
other private equity financing arrangements
related corporate governance, executive compensation, securities law compliance
due diligence issues.
Counsel to both buyers
sellers in public
private acquisition
divestiture transactions, including assistance with structuring the transaction from business
tax perspectives, undertaking due diligence, negotiating
drafting the documentation,
closing
post-closing representation.
Counsel to public companies in connection with securities regulation reporting
financing activities.
Counsel to biotechnology
other life science companies in the structure, negotiation
drafting of various types of technology transfer, licensing
collaboration agreements relating to novel technologies.
Counsel to private equity funds, including structuring
formation advice, assisting with the preparation of offering materials
securities law compliance in raising capital,
representing the funds in structuring
making investments in portfolio companies
real estate transactions.
